Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | IMMX |
---|---|---|
09:32 ET | 8770 | 1.49 |
09:34 ET | 525 | 1.48 |
09:39 ET | 600 | 1.475 |
09:41 ET | 980 | 1.47 |
09:54 ET | 400 | 1.48 |
10:01 ET | 1000 | 1.4797 |
10:03 ET | 753 | 1.4894 |
10:06 ET | 2000 | 1.49 |
10:15 ET | 500 | 1.4846 |
10:17 ET | 9812 | 1.5 |
10:21 ET | 14261 | 1.5 |
10:24 ET | 15470 | 1.5 |
10:26 ET | 20465 | 1.5 |
10:28 ET | 4000 | 1.495259 |
10:39 ET | 3500 | 1.495 |
10:42 ET | 1600 | 1.5 |
10:44 ET | 900 | 1.5 |
10:46 ET | 150 | 1.4901 |
10:51 ET | 6582 | 1.495 |
10:53 ET | 600 | 1.495 |
11:02 ET | 2874 | 1.49 |
11:13 ET | 1000 | 1.5 |
11:18 ET | 1000 | 1.5 |
11:24 ET | 2816 | 1.49 |
11:26 ET | 950 | 1.49 |
11:27 ET | 4000 | 1.4811 |
12:03 ET | 1233 | 1.49 |
12:05 ET | 48961 | 1.5 |
12:07 ET | 2000 | 1.5 |
12:09 ET | 61434 | 1.5 |
12:12 ET | 12300 | 1.5 |
12:14 ET | 11000 | 1.4946 |
12:16 ET | 170 | 1.4907 |
12:25 ET | 5034 | 1.48 |
12:30 ET | 17108 | 1.47 |
12:36 ET | 850 | 1.45 |
12:38 ET | 11846 | 1.46 |
12:43 ET | 2745 | 1.45 |
12:54 ET | 657 | 1.45 |
01:03 ET | 400 | 1.4495 |
01:17 ET | 173 | 1.4408 |
01:19 ET | 700 | 1.45 |
01:30 ET | 1026 | 1.45 |
01:33 ET | 2000 | 1.4489 |
01:35 ET | 300 | 1.45 |
01:46 ET | 5000 | 1.4499 |
01:51 ET | 500 | 1.45 |
01:55 ET | 433 | 1.45 |
02:00 ET | 500 | 1.45 |
02:08 ET | 2500 | 1.449 |
02:13 ET | 995 | 1.4478 |
02:33 ET | 200 | 1.45 |
02:38 ET | 9932 | 1.4499 |
02:47 ET | 100 | 1.4401 |
03:14 ET | 200 | 1.45 |
03:32 ET | 2229 | 1.45 |
03:36 ET | 500 | 1.45 |
03:38 ET | 400 | 1.445 |
03:41 ET | 553 | 1.45 |
03:50 ET | 431 | 1.45 |
03:52 ET | 200 | 1.45 |
03:56 ET | 1467 | 1.47 |
03:57 ET | 1500 | 1.45 |
03:59 ET | 1905 | 1.46 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Immix Biopharma Inc | 40.6M | -1.7x | --- |
vTv Therapeutics Inc | 40.8M | -2.1x | --- |
Lantern Pharma Inc | 40.5M | -2.3x | --- |
Aeon Biopharma Inc | 40.3M | -0.1x | --- |
Achilles Therapeutics PLC | 41.1M | -0.6x | --- |
Passage Bio Inc | 40.1M | -0.5x | --- |
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $40.6M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 27.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.84 |
Book Value | $0.82 |
P/E Ratio | -1.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.